JPH08511525A - Hiv伝播の合成ペプチド抑制物質 - Google Patents
Hiv伝播の合成ペプチド抑制物質Info
- Publication number
- JPH08511525A JPH08511525A JP7501831A JP50183195A JPH08511525A JP H08511525 A JPH08511525 A JP H08511525A JP 7501831 A JP7501831 A JP 7501831A JP 50183195 A JP50183195 A JP 50183195A JP H08511525 A JPH08511525 A JP H08511525A
- Authority
- JP
- Japan
- Prior art keywords
- virus
- peptide
- group
- hiv
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 299
- 230000005540 biological transmission Effects 0.000 title claims description 19
- 239000003112 inhibitor Substances 0.000 title description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 104
- 150000001413 amino acids Chemical class 0.000 claims abstract description 95
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 71
- 241000725303 Human immunodeficiency virus Species 0.000 claims abstract description 51
- 241000282414 Homo sapiens Species 0.000 claims abstract description 29
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 25
- 241000700605 Viruses Species 0.000 claims description 108
- 238000000034 method Methods 0.000 claims description 79
- 125000000539 amino acid group Chemical group 0.000 claims description 43
- 230000000694 effects Effects 0.000 claims description 39
- 230000003612 virological effect Effects 0.000 claims description 25
- 208000031886 HIV Infections Diseases 0.000 claims description 24
- 208000015181 infectious disease Diseases 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 22
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 20
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 19
- 125000001165 hydrophobic group Chemical group 0.000 claims description 19
- -1 9-fluorenylmethoxy-carbonyl group Chemical group 0.000 claims description 17
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 14
- 238000006467 substitution reaction Methods 0.000 claims description 14
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 13
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 9
- 125000003368 amide group Chemical group 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 230000009385 viral infection Effects 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 8
- 241000713311 Simian immunodeficiency virus Species 0.000 claims description 7
- 230000028993 immune response Effects 0.000 claims description 7
- 238000003780 insertion Methods 0.000 claims description 7
- 230000037431 insertion Effects 0.000 claims description 7
- 241000711404 Avian avulavirus 1 Species 0.000 claims description 5
- 241000712083 Canine morbillivirus Species 0.000 claims description 5
- 208000037357 HIV infectious disease Diseases 0.000 claims description 5
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- 230000001177 retroviral effect Effects 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 241000714266 Bovine leukemia virus Species 0.000 claims description 2
- 241000714165 Feline leukemia virus Species 0.000 claims description 2
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 claims description 2
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 2
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims 8
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 241000714174 Feline sarcoma virus Species 0.000 claims 1
- 241001494479 Pecora Species 0.000 claims 1
- 241000714205 Woolly monkey sarcoma virus Species 0.000 claims 1
- 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 108010032976 Enfuvirtide Proteins 0.000 abstract description 193
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 abstract description 184
- 101800001690 Transmembrane protein gp41 Proteins 0.000 abstract description 54
- 230000003389 potentiating effect Effects 0.000 abstract description 6
- 239000012634 fragment Substances 0.000 abstract description 5
- 230000000798 anti-retroviral effect Effects 0.000 abstract description 3
- 235000001014 amino acid Nutrition 0.000 description 106
- 229940024606 amino acid Drugs 0.000 description 100
- 150000001875 compounds Chemical class 0.000 description 70
- 210000004027 cell Anatomy 0.000 description 67
- 230000000840 anti-viral effect Effects 0.000 description 61
- 238000003556 assay Methods 0.000 description 46
- 108090000623 proteins and genes Proteins 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 37
- 238000012360 testing method Methods 0.000 description 29
- 230000004927 fusion Effects 0.000 description 26
- 102100034349 Integrase Human genes 0.000 description 24
- 230000003993 interaction Effects 0.000 description 23
- 108020001507 fusion proteins Proteins 0.000 description 22
- 102000037865 fusion proteins Human genes 0.000 description 21
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 239000002253 acid Substances 0.000 description 17
- 210000004899 c-terminal region Anatomy 0.000 description 17
- 230000015572 biosynthetic process Effects 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- 230000001404 mediated effect Effects 0.000 description 13
- 101100107610 Arabidopsis thaliana ABCF4 gene Proteins 0.000 description 12
- 101100068078 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GCN4 gene Proteins 0.000 description 12
- 230000007910 cell fusion Effects 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000013461 design Methods 0.000 description 11
- 230000035772 mutation Effects 0.000 description 11
- 101710090322 Truncated surface protein Proteins 0.000 description 10
- 230000036436 anti-hiv Effects 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 206010025135 lupus erythematosus Diseases 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- 208000030507 AIDS Diseases 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 101710155964 Diuretic hormone 1 Proteins 0.000 description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 7
- 108010038807 Oligopeptides Proteins 0.000 description 7
- 102000015636 Oligopeptides Human genes 0.000 description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 7
- 230000002155 anti-virotic effect Effects 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 101000818752 Homo sapiens Zinc finger protein 17 Proteins 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 6
- 102100021376 Zinc finger protein 17 Human genes 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000002983 circular dichroism Methods 0.000 description 6
- 230000004850 protein–protein interaction Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 101001120470 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Peptidoglycan-associated lipoprotein Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000008298 dragée Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 101150048348 GP41 gene Proteins 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- 241001024304 Mino Species 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000007791 liquid phase Substances 0.000 description 4
- 230000034217 membrane fusion Effects 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 108091005703 transmembrane proteins Proteins 0.000 description 4
- 102000035160 transmembrane proteins Human genes 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 101800000022 Fusion glycoprotein F1 Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000711920 Human orthopneumovirus Species 0.000 description 3
- 241000519695 Ilex integra Species 0.000 description 3
- 206010061598 Immunodeficiency Diseases 0.000 description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 description 3
- 241000712431 Influenza A virus Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000007813 immunodeficiency Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 101800001622 120 kDa surface-exposed protein Proteins 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100028906 Catenin delta-1 Human genes 0.000 description 2
- 241000252233 Cyprinus carpio Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000712003 Human respirovirus 3 Species 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010001441 Phosphopeptides Proteins 0.000 description 2
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 2
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003141 anti-fusion Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000009918 complex formation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000007499 fusion processing Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000219 mutagenic Toxicity 0.000 description 2
- 230000003505 mutagenic effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 2
- GKBMIFPNPOSTHB-BJBKLNMKSA-N recombinant soluble cd4 Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GKBMIFPNPOSTHB-BJBKLNMKSA-N 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000010845 search algorithm Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012916 structural analysis Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000013595 supernatant sample Substances 0.000 description 2
- 230000017960 syncytium formation Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- FAOSXBASBLDSBE-LZGXBFJGSA-N (4S)-5-[[(2S)-6-amino-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-phenylethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-4-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 FAOSXBASBLDSBE-LZGXBFJGSA-N 0.000 description 1
- KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- ZQXCQTAELHSNAT-UHFFFAOYSA-N 1-chloro-3-nitro-5-(trifluoromethyl)benzene Chemical compound [O-][N+](=O)C1=CC(Cl)=CC(C(F)(F)F)=C1 ZQXCQTAELHSNAT-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000490494 Arabis Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000003910 Baronia <angiosperm> Species 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 241000905957 Channa melasoma Species 0.000 description 1
- 101710086578 Chaperone protein gp12 Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 240000005702 Galium aparine Species 0.000 description 1
- 235000014820 Galium aparine Nutrition 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 101001030211 Homo sapiens Myc proto-oncogene protein Proteins 0.000 description 1
- 101100029888 Homo sapiens PKD1 gene Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710175243 Major antigen Proteins 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101150056230 PKD1 gene Proteins 0.000 description 1
- 101150005926 Pc gene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 101710102575 Pre-neck appendage protein Proteins 0.000 description 1
- 241000208474 Protea Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000245165 Rhododendron ponticum Species 0.000 description 1
- 241000231739 Rutilus rutilus Species 0.000 description 1
- 108010072476 SIV envelope protein gp41 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108700022715 Viral Proteases Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N benzyl alcohol Substances OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- 229960004217 benzyl alcohol Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008073 immune recognition Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000003415 peat Substances 0.000 description 1
- 108010091748 peptide A Proteins 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 239000005297 pyrex Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000002976 reverse transcriptase assay Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006298 saran Polymers 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002723 toxicity assay Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007486 viral budding Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- C07K14/16—HIV-1 ; HIV-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
- C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/974—Aids related test
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/826—Viruses
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ウイルスエンベロープタンパク質の細胞外ドメインのαヘリックス領域に対 応するアミノ酸配列を有するペプチドであって、高次コイル構造を有するロイシ ンジッパードメインを含む該ウイルスエンベロープタンパク質の第2のαヘリッ クス領域と相互作用してそれに結合する上記ペプチド。 2.前記ペプチドがALLMOTI5モチーフ、107x178x4モチーフまたはPLZIPモチーフ を用いるコンピュータによるペプチド配列検索により認識されるものである、請 求項1に記載のペプチド。 3.エンベロープを有するウイルスがレトロウイルスである、請求項1に記載の ペプチド。 4.レトロウイルスがヒトレトロウイルスである、請求項3に記載のペプチド。 5.ヒトレトロウイルスがHIV−1またはHIV−2である、請求項4に記載 のペプチド。 6.ヒトレトロウイルスがHTLV−IまたはHTLV−IIである、請求項4に 記載のペプチド。 7.エンベロープを有するウイルスが非ヒトレトロウイルスである、請求項1に 記載のペプチド。 8.非ヒトレトロウイルスがウシ白血症ウイルス、ネコ肉腫ウイルス、ネコ白血 病ウイルス、サル免疫不全ウイルス、サル肉腫ウイルスまたはヒツジ進行性肺炎 ウイルスである、請求項6に記載のペプチド。 9.エンベロープを有するウイルスがレトロウイルス以外のウイル スである、請求項1に記載のペプチド。 10.前記ウイルスがRS(respiratory syncytial)ウイルス、インフルエンザ ウイルス、パラインフルエンザウイルス、イヌジステンパーウイルスまたはニュ ーカッスル病ウイルスである、請求項9に記載のペプチド。 11.次式: (式中、 アミノ酸残基は一文字表記で表してあり、 Xはアミノ基、アセチル基、9−フルオレニルメトキシ−カルボニル基、 疎水基または巨大分子担体グループを含み、 Zはカルボキシル基、アミド基、疎水基または巨大分子担体グループを含 む) よりなる群から選ばれる式を有するペプチド。 12.次式: (式中、 アミノ酸残基は一文字表記で表してあり、 Xはアミノ基、アセチル基、9−フルオレニルメトキシ−カルボニル基、 疎水基または巨大分子担体グループを含み、 Zはカルボキシル基、アミド基、疎水基または巨大分子担体グループを含 む) よりなる群から選ばれる式を有するペプチド。 13.次式: (式中、 アミノ酸残基は一文字表記で表してあり、 Xはアミノ基、アセチル基、9−フルオレニルメトキシ−カルボニル基、 疎水基または巨大分子担体グループを含み、 Zはカルボキシル基、アミド基、疎水基または巨大分子担体グループを含 む) よりなる群から選ばれる式を有するペプチド。 14.次式: (式中、 アミノ酸残基は一文字表記で表してあり、 Xはアミノ基、アセチル基、9−フルオレニルメトキシ−カルボニル基、 疎水基または巨大分子担体グループを含み、 Zはカルボキシル基、アミド基、疎水基または巨大分子担体グループを含 む) よりなる群から選ばれる式を有するペプチド。 15.次式: (式中、 アミノ酸残基は一文字表記で表してあり、 Xはアミノ基、アセチル基、9−フルオレニルメトキシ−カルボニル基、 疎水基または巨大分子担体グループを含み、 Zはカルボキシル基、アミド基、疎水基または巨大分子担体グループを含 む) よりなる群から選ばれる式を有するペプチド。 16.次式: (式中、 アミノ酸残基は一文字表記で表してあり、 Xはアミノ基、アセチル基、9−フルオレニルメトキシ−カルボニル基、 疎水基または巨大分子担体グループを含み、 Zはカルボキシル基、アミド基、疎水基または巨大分子担体グループを含 む) よりなる群から選ばれる式を有するペプチド。 17.Xが疎水基である、請求項11、12、13、14、15または16に記載のペプチド。 18.疎水基Xがカルボベンゾキシル、ダンシルまたはt−ブチルオキシカルボニ ルである、請求項17に記載のペプチド。 19.Zが疎水基である、請求項11、12、13、14、15または16に記載のペプチド。 20.疎水基Zがt−ブチルオキシカルボニルである、請求項19に記載のペプチド 。 21.Xが巨大分子担体グループである、請求項11、12、13、14、15または16に記 載のペプチド。 22.巨大分子担体グループが脂質−脂肪酸結合体、ポリエチレングリコールまた は炭水化物成分である、請求項21に記載のペプチド。 23.Zが巨大分子担体グループである、請求項11、12、13、14、15または16に記 載のペプチド。 24.巨大分子担体グループZが脂質−脂肪酸結合体、ポリエチレングリコールま たは炭水化物成分である、請求項23に記載のペプチド。 25.隣接アミノ酸残基を連結している少なくとも1つの結合が非ペプチド結合で ある、請求項11、12、13、14、15または16に記載のペプチド。 26.非ペプチド結合がイミノ、エステル、ヒドラジン、セミカルバジドまたはア ゾ結合である、請求項25に記載のペプチド。 27.少なくとも1個のアミノ酸残基がD異性体の配置にある、請求項11、12、13 、14、15または16に記載のペプチド。 28.少なくとも1個のアミノ酸の挿入をさらに含む、請求項11、12、13、14、15 または16に記載のペプチド。 29.アミノ酸の挿入が1〜15個のアミノ酸残基である、請求項11、12、13、14 、15または16に記載のペプチド。 30.アミノ酸残基がアミノ酸の欠失を表し、前記ペプチドが少なくとも3個のア ミノ酸残基を含んでなる、少なくとも1個少ないアミノ酸残基を有する請求項11 、12、13、14、15または16に記載のペプチド。 31.第1のアミノ酸残基が第2の異なるアミノ酸残基で置換される少なくとも1 個のアミノ酸の置換をさらに含む、請求項11、12、13、14、15または16に記載の ペプチド。 32.アミノ酸の置換が保存的置換である、請求項31に記載のペプチド。 33.アミノ酸の置換が非保存的置換である、請求項31に記載のペプチド。 34.エンベロープを有するウイルスの細胞への伝播を抑制する方法であって、細 胞と有効濃度の請求項1のペプチドとを効果的な期間にわたり接触させて、該ウ イルスによる細胞の感染が起こらないようにすることを含んでなる上記方法。 35.宿主内のエンベロープを有するウイルスを中和する方法であって、宿主に有 効濃度の請求項1のペプチドを投与して、宿主において該ウイルスを中和するの に十分な免疫応答を引き出し、かつ宿主の未感染細胞のウイルス感染を抑制する ようにすることを含んでなる上記方法。 36.宿主内のエンベロープを有するウイルスを中和する方法であって、宿主に、 有効濃度の請求項1のペプチドに対する抗体を投与して、宿主内の未感染細胞の ウイルス感染を抑制するようにすることを含んでなる上記方法。 37.エンベロープを有するウイルスの検出方法であって、 ウイルス単離物と有効濃度の請求項1のペプチドとを効果的な期間にわたり 接触させてウイルスの感染性を抑制し、そして ウイルスの酵素活性について該ウイルス単離物をアッセイする、ことを含ん でなる上記方法。 38.HIVレトロウイルスの細胞への伝播を抑制する方法であって、細胞と有効 濃度の請求項11または12のペプチドとを効果的な期間にわたり接触させることに より、該レトロウイルスによる細胞の 感染が起こらないようにすることを含んでなる上記方法。 39.宿主内のHIVレトロウイルスを中和する方法であって、宿主に、有効濃度 の請求項11または12のペプチドを投与して、宿主においてHIVレトロウイルス を中和するのに十分な免疫応答を引き出し、かつ宿主内の未感染細胞のHIV感 染を抑制するようにすることを含んでなる上記方法。 40.宿主内のHIVレトロウイルスを中和する方法であって、宿主に、有効濃度 の請求項11または12のペプチドに対する抗体を投与して、宿主内の未感染細胞の HIV感染を抑制するようにすることを含んでなる上記方法。 41.HIVを検出する方法であって、 ウイルス単離物と有効濃度の請求項11または12のペプチドとを効果的な期間 にわたり接触させてHIVウイルスの感染性を抑制し、そして レトロウイルスの酵素活性について該ウイルス単離物をアッセイする、 ことを含んでなる上記方法。 42.RS(respiratory syncytial)ウイルスの細胞への伝播を抑制する方法で あって、細胞と有効濃度の請求項13または14のペプチドとを効果的な期間にわた り接触させることにより、該ウイルスによる細胞の感染が起こらないようにする ことを含んでなる上記方法。 43.宿主内のRSウイルスを中和する方法であって、宿主に、有効濃度の請求項 13または14のペプチドを投与して、宿主において該ウイルスを中和するのに十分 な免疫応答を引き出し、かつ宿主内 の未感染細胞のRSウイルス感染を抑制するようにすることを含んでなる上記方 法。 44.宿主内のRSウイルスを中和する方法であって、宿主に、有効濃度の請求項 13または14のペプチドに対する抗体を投与して、宿主内の未感染細胞のRSウイ ルス感染を抑制するようにすることを含んでなる上記方法。 45.RSウイルスを検出する方法であって、 ウイルス単離物と有効濃度の請求項13または14のペプチドとを効果的な期間 にわたり接触させてRSウイルスの感染性を抑制し、そして RSウイルスの酵素活性について該ウイルス単離物をアッセイする、 ことを含んでなる上記方法。 46.パラインフルエンザウイルスの細胞への伝播を抑制する方法であって、細胞 と有効濃度の請求項15または16のペプチドとを効果的な期間にわたり接触させる ことにより、該ウイルスによる細胞の感染が起こらないようにすることを含んで なる上記方法。 47.宿主内のパラインフルエンザウイルスを中和する方法であって、宿主に、有 効濃度の請求項15または16のペプチドを投与して、宿主において該ウイルスを中 和するのに十分な免疫応答を引き出し、かつ宿主内の未感染細胞のパラインフル エンザ感染を抑制するようにすることを含んでなる上記方法。 48.宿主内のパラインフルエンザウイルスを中和する方法であって、宿主に、有 効濃度の請求項15または16のペプチドに対する抗体を投与して、宿主内の未感染 細胞のパラインフルエンザ感染を抑制 するようにすることを含んでなる上記方法。 49.パラインフルエンザウイルスを検出する方法であって、 ウイルス単離物と有効濃度の請求項15または16のペプチドとを効果的な期間 にわたり接触させてパラインフルエンザウイルスの感染性を抑制し、そして パラインフルエンザウイルスの酵素活性について該ウイルス単離物をアッセ イする、 ことを含んでなる上記方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/073,028 US5464933A (en) | 1993-06-07 | 1993-06-07 | Synthetic peptide inhibitors of HIV transmission |
US073,028 | 1993-06-07 | ||
PCT/US1994/005739 WO1994028920A1 (en) | 1993-06-07 | 1994-06-07 | Synthetic peptide inhibitors of hiv transmission |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH08511525A true JPH08511525A (ja) | 1996-12-03 |
JP4205159B2 JP4205159B2 (ja) | 2009-01-07 |
Family
ID=22111275
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50183195A Expired - Fee Related JP4205159B2 (ja) | 1993-06-07 | 1994-06-07 | Hiv伝播の合成ペプチド抑制物質 |
Country Status (16)
Country | Link |
---|---|
US (4) | US5464933A (ja) |
EP (2) | EP0774971B1 (ja) |
JP (1) | JP4205159B2 (ja) |
KR (1) | KR100355407B1 (ja) |
AT (1) | ATE293127T1 (ja) |
AU (1) | AU692777B2 (ja) |
CA (1) | CA2164698C (ja) |
CL (1) | CL2009002139A1 (ja) |
DE (2) | DE69434335T2 (ja) |
DK (1) | DK0774971T3 (ja) |
ES (1) | ES2238674T3 (ja) |
LU (1) | LU91166I2 (ja) |
NL (1) | NL300192I2 (ja) |
NZ (3) | NZ501727A (ja) |
PT (1) | PT774971E (ja) |
WO (1) | WO1994028920A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002507576A (ja) * | 1998-03-23 | 2002-03-12 | トリメリス,インコーポレーテッド | ペプチド合成のための方法および組成物 |
JP2003504344A (ja) * | 1999-07-09 | 2003-02-04 | トリメリス,インコーポレーテッド | 増強された薬物動態学的性質をもつハイブリッドポリペプチド |
JP2003522948A (ja) * | 2000-02-10 | 2003-07-29 | パナコス ファーマシューティカルズ, インコーポレイテッド | ウイルス融合インヒビターの検出のための分析 |
JP2003530311A (ja) * | 1999-07-07 | 2003-10-14 | トリメリス,インコーポレーテッド | ペプチド合成の方法および組成物 |
WO2008050830A1 (fr) * | 2006-10-25 | 2008-05-02 | Kyoto University | Agent anti-vih |
JP2010065044A (ja) * | 1998-03-23 | 2010-03-25 | Trimeris Inc | ペプチド合成のための方法および組成物 |
Families Citing this family (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070202127A1 (en) * | 1993-06-07 | 2007-08-30 | Duke University | Nucleic acids encoding DP-178 and other viral fusion inhibitor peptides useful for treating aids |
US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
GB9501300D0 (en) * | 1995-01-24 | 1995-03-15 | Boughton Brian J | Peptides which inhibit viruses |
NZ311319A (en) * | 1995-06-07 | 2000-01-28 | Trimeris Inc | The treatment of HIV and other viral infections using the peptide DP-178 or DP-107 in combination therapy |
AU4251197A (en) * | 1996-09-06 | 1998-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Therapeutic chemokine antagonists |
US6271198B1 (en) * | 1996-11-06 | 2001-08-07 | Genentech, Inc. | Constrained helical peptides and methods of making same |
WO1998029121A1 (en) * | 1997-01-02 | 1998-07-09 | Thomas Jefferson University | A method of modulating an immune response in an infected mammal by transmucosal administration of modulating agent |
AU6649698A (en) * | 1997-01-28 | 1998-08-18 | Regents Of The University Of California, The | Peptide probes to coil proteins and methods for making the same |
US6150088A (en) | 1997-04-17 | 2000-11-21 | Whitehead Institute For Biomedical Research | Core structure of gp41 from the HIV envelope glycoprotein |
US6841657B2 (en) | 1997-04-17 | 2005-01-11 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
US6818740B1 (en) | 1997-04-17 | 2004-11-16 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
US6258782B1 (en) | 1998-05-20 | 2001-07-10 | Trimeris, Inc. | Hybrid polypeptides with enhanced pharmacokinetic properties |
US6747126B1 (en) * | 1998-07-30 | 2004-06-08 | Whitehead Institute For Biomedical Research | Peptide inhibitors of HIV entry |
US7960504B2 (en) * | 1998-07-30 | 2011-06-14 | Whitehead Institute For Biomedical Research | Inhibitors of HIV membrane fusion |
AU2004201386B2 (en) * | 1998-09-04 | 2008-08-28 | Ortho-Mcneil Pharmaceutical, Inc. | 5-heterocyclyl pyrazolo[4,3-d]pyrimidin-7-ones for the treatment of male erectile dysfunction |
AU2604200A (en) * | 1999-01-08 | 2000-07-24 | Panacos Pharmaceuticals, Inc. | Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41 |
BR0010757A (pt) * | 1999-05-17 | 2002-02-19 | Conjuchem Inc | Inibidores de peptìdeo de fusão de longa duração de infecção viral |
US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
US6541020B1 (en) * | 1999-07-09 | 2003-04-01 | Trimeris, Inc. | Methods and compositions for administration of therapeutic reagents |
SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
WO2001044286A2 (en) | 1999-12-16 | 2001-06-21 | Whitehead Institute For Biomedical Research | Five-helix protein |
US20030082525A1 (en) * | 1999-12-16 | 2003-05-01 | Whitehead Institute For Biomedical Research | Five-Helix protein |
US6692745B2 (en) * | 2000-01-28 | 2004-02-17 | Arogenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
US6623741B1 (en) | 2000-02-29 | 2003-09-23 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission |
US6528308B1 (en) * | 2000-03-16 | 2003-03-04 | Duke University | Suppressor of HIV replication and transcription |
NZ521977A (en) * | 2000-03-17 | 2004-05-28 | Panacos Pharmaceuticals Inc | A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of HIV envelope proteins |
US7790171B1 (en) * | 2000-08-25 | 2010-09-07 | Centre National De La Recherche Scientifique (C.N.R.S.) | Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase |
US7138119B2 (en) | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
US20050065319A1 (en) * | 2000-12-19 | 2005-03-24 | Baroudy Bahige M. | Combination method for treating viral infections |
WO2002079157A1 (en) | 2001-03-29 | 2002-10-10 | Schering Corporation | Aryl oxime-piperazines useful as ccr5 antagonists |
US7202354B2 (en) * | 2001-03-30 | 2007-04-10 | Abbott Laboratories | Hepatitis B virus surface antigen mutant and methods of detection thereof |
WO2002103026A2 (en) * | 2001-06-15 | 2002-12-27 | F. Hoffmann-La Roche Ag | Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments |
US20030027867A1 (en) * | 2001-06-29 | 2003-02-06 | Myriad Genetics, Incorporated | Use of R-NSAID compounds for anti-HIV treatment |
WO2003006056A2 (en) * | 2001-07-11 | 2003-01-23 | Genfa Zhou | End-locked five-helix protein |
US20030226155A1 (en) * | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
ATE490969T1 (de) * | 2001-08-30 | 2010-12-15 | Biorexis Pharmaceutical Corp | Modifizierte transferrin-fusionsproteine |
US8129504B2 (en) | 2001-08-30 | 2012-03-06 | Biorexis Technology, Inc. | Oral delivery of modified transferrin fusion proteins |
US20070031440A1 (en) * | 2001-08-30 | 2007-02-08 | Prior Christopher P | Modified transferin-antibody fusion proteins |
WO2003048187A2 (en) * | 2001-11-29 | 2003-06-12 | Mymetics, Corp. | Peptides and use thereof in therapeutic agents against hiv infection |
US20030125518A1 (en) * | 2001-12-01 | 2003-07-03 | Crevecoeur Harry F. | Surface simulation synthetic peptides useful in the treatment of hyper-variable viral pathogens |
US20060241027A1 (en) * | 2002-02-07 | 2006-10-26 | Hans-Peter Hauser | Hiv inhibiting proteins |
CA2485064A1 (en) * | 2002-02-07 | 2003-08-14 | Delta Biotechnology Limited | Albumin-fused kunitz domain peptides |
RU2322454C2 (ru) | 2002-02-22 | 2008-04-20 | Проджиникс Фармасьютикалз, Инк. | Антитело против ccr5 |
KR100451432B1 (ko) * | 2002-07-12 | 2004-10-06 | 강충경 | T-20 펩타이드의 생물학적 제조방법 |
EP1546193A1 (en) * | 2002-07-24 | 2005-06-29 | F. Hoffmann-La Roche Ag | Pegylated t1249 polypeptide |
RU2296769C2 (ru) * | 2002-07-24 | 2007-04-10 | Ф.Хоффманн-Ля Рош Аг | Пэгилированный полипептид т20 |
US20060105387A1 (en) * | 2002-08-30 | 2006-05-18 | Prior Christopher P | Transferrin fusion proteins libraries |
US20040076637A1 (en) * | 2002-09-27 | 2004-04-22 | Delmedico Mary Kay | HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus |
WO2004028473A2 (en) * | 2002-09-27 | 2004-04-08 | Tanox, Inc. | Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
CN100444848C (zh) * | 2002-09-27 | 2008-12-24 | 特里梅里斯公司 | HIV gp41-衍生肽的改善用药的药物组合物 |
US7045552B2 (en) * | 2002-09-27 | 2006-05-16 | Trimeris, Inc. | Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy |
US7556813B2 (en) * | 2002-09-27 | 2009-07-07 | Trimeris, Inc. | Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides |
WO2004035808A2 (en) * | 2002-10-16 | 2004-04-29 | Panacos Pharmaceuticals, Inc. | Method for detecting viral inactivating agents |
CA2443365C (en) * | 2002-11-19 | 2010-01-12 | F. Hoffmann-La Roche Ag | Methods for the recombinant production of antifusogenic peptides |
US20070060512A1 (en) * | 2003-03-04 | 2007-03-15 | Homayoun Sadeghi | Dipeptidyl-peptidase protected protein |
EP1608629A1 (en) | 2003-03-24 | 2005-12-28 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
AU2004223829A1 (en) * | 2003-03-24 | 2004-10-07 | Sequoia Pharmaceuticals, Inc. | Long acting biologically active conjugates |
EP1617865A4 (en) * | 2003-03-31 | 2008-04-09 | Us Gov Health & Human Serv | IMPROVED HIV-1 VACCINES AND METHODS OF USE |
PL2077121T3 (pl) * | 2003-05-06 | 2011-07-29 | Syntonix Pharmaceuticals Inc | Białka chimeryczne o strukturze czynnik krzepliwości krwi VII-FC do leczenia zaburzenia hemostatycznego |
US7348004B2 (en) * | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
TWI353991B (en) * | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
US20050281829A1 (en) * | 2003-05-06 | 2005-12-22 | Hehir Cristina A T | Fc chimeric proteins with anti-HIV drugs |
US7379700B2 (en) * | 2003-05-06 | 2008-05-27 | Canon Kabushiki Kaisha | Image reading apparatus with rotatable internal and external guides |
WO2004108886A2 (en) * | 2003-05-08 | 2004-12-16 | Anderson Porter W | Anti-hiv-1 compounds based upon a conserved amino acid sequence shared by gp160 and the human cd4 protein |
WO2005034842A2 (en) * | 2003-05-19 | 2005-04-21 | Progenics Pharmaceuticals, Inc. | Peptides useful as hiv fusion inhibitors |
WO2005018666A1 (en) * | 2003-08-14 | 2005-03-03 | The Government Of The United States Of America, As Represented By The Department Of Health And Human Services | Polypeptide multimers having antiviral activity |
US20060205037A1 (en) * | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
JP2007512001A (ja) * | 2003-08-28 | 2007-05-17 | バイオレクシス ファーマシューティカル コーポレイション | Epoミメティックペプチドおよび融合タンパク質 |
KR20050024730A (ko) * | 2003-09-01 | 2005-03-11 | 코바이오텍 (주) | T―20 펩타이드 코딩 유전자를 포함하는 재조합대장균의 고농도 세포 배양 방법 및 이로부터 생산된t―20 펩타이드의 분리 및 정제 방법 |
ATE518967T1 (de) | 2003-11-04 | 2011-08-15 | Univ Tulane | Verfahren zur verhinderung einer virus-zelle- fusion durch hemmen der funktion des fusionsinitiierungsbereichs in rna-viren mit klasse-i-membranfusogenen hüllproteinen |
EP1696943A4 (en) * | 2003-12-22 | 2007-09-19 | Yeda Res & Dev | PEPTIDES DIASTEREOMERS USEFUL AS INHIBITORS OF MEMBRANE PROTEIN ASSEMBLY |
US7744897B2 (en) | 2003-12-23 | 2010-06-29 | Dillon Susan B | Human immunodeficiency virus gp41 mimetibody polypeptides |
WO2005063799A2 (en) * | 2003-12-31 | 2005-07-14 | F.Hoffmann-La Roche Ag | Peptide synthesis and deprotection with co-solvent |
EP1701972B1 (en) * | 2003-12-31 | 2008-10-08 | F. Hoffmann-La Roche Ag | Process and systems for recovery of peptides |
WO2005063792A2 (en) * | 2003-12-31 | 2005-07-14 | F. Hoffmann-La Roche Ag | Methods for recovering cleaved peptide from a support |
WO2005063800A2 (en) * | 2003-12-31 | 2005-07-14 | F. Hoffmann-La Roche Ag | Peptide synthesis using decanting filter |
DE602004009710T2 (de) * | 2003-12-31 | 2008-08-07 | F. Hoffmann-La Roche Ag | Verfahren zur peptidsynthese unter verwendung einer reduzierten menge an entschützungsmittel |
CA2551082A1 (en) * | 2004-01-07 | 2005-07-28 | Trimeris, Inc. | Hiv gp41 hr2-derived synthetic peptides, and their use in therapy to inhibit transmission of human immunodeficiency virus |
US20080027006A1 (en) * | 2004-02-12 | 2008-01-31 | The Regents Of The University Of Colorado | Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity |
DE602005016658D1 (de) * | 2004-04-08 | 2009-10-29 | Jadolabs Gmbh | Dreigeteilte konjugate mit einer struktur, die mit zellmembran-rafts interagieren und ihre verwendung |
US20080039532A1 (en) * | 2004-05-06 | 2008-02-14 | Dominique Bridon | Compounds For Specific Viral Target |
JP5069558B2 (ja) * | 2004-06-01 | 2012-11-07 | メルク・シャープ・エンド・ドーム・コーポレイション | HIVgp41融合中間物質の安定したペプチド模倣薬 |
ATE516048T1 (de) * | 2004-06-01 | 2011-07-15 | Merck Sharp & Dohme | Mit hiv gp41 in wechselwirkung stehende menschliche antikörper |
GB0415160D0 (en) * | 2004-07-06 | 2004-08-11 | Chiron Srl | Inhibitors of bacterial infection |
WO2006069779A1 (en) * | 2004-12-30 | 2006-07-06 | F. Hoffmann-La Roche Ag | Preparing of peptides with excellent solubility |
ES2329270T3 (es) * | 2004-12-30 | 2009-11-24 | F. Hoffmann-La Roche Ag | Sintesis del peptido t-1249 utilizando fragmentos intermediarios del ipeptido. |
CN101133077B (zh) * | 2004-12-30 | 2012-09-05 | 弗·哈夫曼-拉罗切有限公司 | 使用肽中间片段合成肽t-20 |
US20090270312A1 (en) * | 2005-01-24 | 2009-10-29 | Yechiel Shai | Hiv-i gp41 fusion peptides for immunomodulaltion |
US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
AU2006223161B2 (en) * | 2005-03-11 | 2011-05-12 | Endo Pharmaceuticals Solutions Inc. | Controlled release formulations of octreotide |
EP1868652A2 (en) * | 2005-04-05 | 2007-12-26 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Method for shielding functional sites or epitopes on proteins |
WO2007045573A1 (en) | 2005-10-19 | 2007-04-26 | F. Hoffmann-La Roche Ag | Phenyl-acetamide nnrt inhibitors |
JP2009514533A (ja) * | 2005-11-02 | 2009-04-09 | アンブルックス,インコーポレイテッド | 生合成ポリペプチド融合阻害剤 |
AR059300A1 (es) * | 2006-02-02 | 2008-03-26 | Trimeris Inc | Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas |
EP2319542B1 (en) * | 2006-02-21 | 2018-03-21 | Nektar Therapeutics | Segmented degradable polymers and conjugates made therefrom |
US8222204B2 (en) * | 2006-05-03 | 2012-07-17 | The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC | Influenza inhibiting compositions and methods |
ATE524493T1 (de) * | 2006-07-24 | 2011-09-15 | Biorexis Pharmaceutical Corp | Exendin-fusionsproteine |
PL2057125T3 (pl) | 2006-08-16 | 2011-09-30 | Hoffmann La Roche | Nienukleozydowe inhibitory odwrotnej transkryptazy |
MX2009001204A (es) | 2006-08-17 | 2009-02-11 | Hoffmann La Roche | Conjugado de un anticuerpo cointra ccr5 y un peptido antifusogenico. |
TW200817438A (en) * | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
KR20090098880A (ko) | 2006-12-12 | 2009-09-17 | 바이오렉시스 파마슈티칼 코포레이션 | 트랜스페린 융합 단백질 라이브러리 |
JP5415957B2 (ja) | 2006-12-13 | 2014-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素阻害剤としての2−(ピペリジン−4−イル)−4−フェノキシ−又はフェニルアミノ−ピリミジン誘導体 |
US20090088378A1 (en) * | 2007-01-12 | 2009-04-02 | Omar Quraishi | Long lasting inhibitors of viral infection |
TW200902544A (en) | 2007-03-13 | 2009-01-16 | Hoffmann La Roche | Peptide-complement conjugates |
MX2009010689A (es) * | 2007-04-03 | 2009-12-14 | Trimeris Inc | Formulaciones novedosas para el suministro de agentes terapeuticos de peptidos antivirales. |
BRPI0811864A2 (pt) * | 2007-05-16 | 2014-11-18 | Conjuchem Biotechnologies Inc | Derivados de ácido cistéico de peptídeos antivirais |
PL2170365T3 (pl) | 2007-06-25 | 2017-03-31 | The Administrators Of The Tulane Educational Fund | Kompozycje i sposoby inhibujące grypę |
AR067584A1 (es) | 2007-07-20 | 2009-10-14 | Hoffmann La Roche | Un conjugado de un anticuerpo contra la cd4 y peptidos antifusogenicos |
WO2009042194A2 (en) * | 2007-09-25 | 2009-04-02 | Trimeris, Inc. | Methods of synthesis for therapeuthic anti-hiv peptides |
AU2009236585B2 (en) * | 2008-04-18 | 2013-03-07 | Vaxinnate Corporation | Deletion mutants of flagellin and methods of use |
RU2521291C2 (ru) * | 2008-06-25 | 2014-06-27 | Эндо Фармасьютикалз Солюшнз Инк. | Имплантат октреотида, содержащий высвобождающее вещество |
US8071537B2 (en) * | 2008-06-25 | 2011-12-06 | Endo Pharmaceuticals Solutions Inc. | Implantable device for the sustained release of a polypeptide |
EP3698811A1 (en) | 2009-06-18 | 2020-08-26 | Dana Farber Cancer Institute, Inc. | Structured viral peptide compositions and methods of use |
EP2493911B1 (en) | 2009-10-30 | 2017-10-18 | The Administrators of The Tulane Educational Fund | Peptide compositions and methods for inhibiting herpesvirus infection |
US8357726B2 (en) * | 2010-01-20 | 2013-01-22 | Vertex L.L.C. | Devulcanization of rubber and other elastomers |
US8470897B2 (en) | 2010-01-20 | 2013-06-25 | Vertex L.L.C. | Devulcanization of rubber and other elastomers |
US20120009212A1 (en) | 2010-01-26 | 2012-01-12 | The Regents Of The University Of Colorado, A Body Corporate | Conjugates utilizing platform technology for stimulating immune response |
WO2011095989A2 (en) | 2010-02-04 | 2011-08-11 | Matrix Laboratories Ltd | An improved process for the preparation of enfuvirtide |
WO2011133948A2 (en) | 2010-04-22 | 2011-10-27 | Longevity Biotech, Inc. | Highly active polypeptides and methods of making and using the same |
EP2616487B1 (en) | 2010-09-14 | 2015-03-25 | F.Hoffmann-La Roche Ag | Serpin-finger fusion polypeptide |
EP2447277A1 (en) | 2010-10-28 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Vaccine compositions based on modified gp41 immunogens |
WO2013127299A1 (zh) * | 2012-02-28 | 2013-09-06 | 中国人民解放军军事医学科学院毒物药物研究所 | 用于抑制hiv的多肽及其作用靶点 |
WO2013150532A1 (en) | 2012-04-04 | 2013-10-10 | Yeda Research And Development Co. Ltd. | Lipopeptide conjugates comprising sphingolipid and hiv gp41 derived peptides |
AU2013295242C1 (en) | 2012-07-27 | 2018-08-09 | Institut National De La Sante Et De La Recherche Medicale | CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
WO2014068265A1 (en) | 2012-10-29 | 2014-05-08 | Cipla Limited | Antiviral phosphonate analogues and process for preparation thereof |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
EA037906B1 (ru) | 2013-03-15 | 2021-06-04 | Биовератив Терапьютикс Инк. | Препараты полипептида фактора ix |
WO2014145718A2 (en) | 2013-03-15 | 2014-09-18 | Longevity Biotech, Inc. | Peptides comprising non-natural amino acids and methods of making and using the same |
UY36990A (es) | 2015-11-21 | 2017-11-30 | Fundació Privada Inst De Recerca De La Sida-Caixa (Irsicaixa) | Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria |
JP2019524687A (ja) | 2016-07-01 | 2019-09-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 抗体薬物複合体およびこれを用いた治療方法 |
US20200157192A1 (en) | 2017-05-10 | 2020-05-21 | Albajuna Therapeutics, S.L. | Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity |
CN111499698B (zh) * | 2020-03-19 | 2023-05-16 | 中国农业科学院特产研究所 | 犬i型腺病毒亚单位疫苗及其制备方法 |
CN112410312A (zh) * | 2020-11-27 | 2021-02-26 | 江南大学 | 一种环己酮单加氧酶及其应用 |
CN117186187A (zh) * | 2023-07-12 | 2023-12-08 | 中国医学科学院病原生物学研究所 | 一种抗呼吸道合胞病毒膜融合抑制剂及其药物用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU617088B2 (en) * | 1986-06-12 | 1991-11-21 | Biogen, Inc. | Peptides involved in the pathogenesis of hiv infection |
US5141867A (en) * | 1987-02-02 | 1992-08-25 | E. I. Du Pont De Nemours And Company | Nucleotide sequence encoding a human immunodeficiency virus antigen |
AU1711888A (en) * | 1987-04-24 | 1988-12-02 | Biogen, Inc. | Immunotherapeutic methods and compositions |
US5223254A (en) * | 1987-09-29 | 1993-06-29 | Praxis Biologics, Inc. | Respiratory syncytial virus: vaccines |
EP0323157A3 (en) | 1987-12-24 | 1990-07-25 | The University Of Melbourne | Antiviral compounds and methods |
EP0362927A3 (en) * | 1988-10-06 | 1990-11-14 | Akzo N.V. | Synthetic polypeptides immunochemically reactive with hiv antibodies |
JP2994031B2 (ja) * | 1988-12-20 | 1999-12-27 | クラリティ テクノロジーズ インコーポレイテッド | Hiv−1又はhiv−2抗体の存在又は量の確定方法、免疫特異的試薬、合成ペプチド、診断用キット、hiv−1又はhiv−2抗体の調製方法、免疫原及び抗体 |
US6248574B1 (en) * | 1989-12-13 | 2001-06-19 | Avigdor Shaffermann | Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides |
IL102092A (en) * | 1991-06-11 | 1996-11-14 | Microgenesys Inc | Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein |
NZ254640A (en) * | 1992-07-20 | 1997-04-24 | Univ Duke | Hiv protein fragments of transmembrane glycoprotein gp41 (dp-107) with antiviral activity and their use |
-
1993
- 1993-06-07 US US08/073,028 patent/US5464933A/en not_active Expired - Lifetime
-
1994
- 1994-06-07 DK DK94919201T patent/DK0774971T3/da active
- 1994-06-07 NZ NZ501727A patent/NZ501727A/en not_active IP Right Cessation
- 1994-06-07 DE DE69434335T patent/DE69434335T2/de not_active Expired - Lifetime
- 1994-06-07 US US08/255,208 patent/US6440656B1/en not_active Expired - Fee Related
- 1994-06-07 NZ NZ329775A patent/NZ329775A/xx unknown
- 1994-06-07 KR KR1019950705528A patent/KR100355407B1/ko not_active IP Right Cessation
- 1994-06-07 WO PCT/US1994/005739 patent/WO1994028920A1/en active IP Right Grant
- 1994-06-07 EP EP94919201A patent/EP0774971B1/en not_active Expired - Lifetime
- 1994-06-07 CA CA2164698A patent/CA2164698C/en not_active Expired - Lifetime
- 1994-06-07 DE DE200512000025 patent/DE122005000025I2/de active Active
- 1994-06-07 PT PT94919201T patent/PT774971E/pt unknown
- 1994-06-07 NZ NZ267803A patent/NZ267803A/xx not_active IP Right Cessation
- 1994-06-07 ES ES94919201T patent/ES2238674T3/es not_active Expired - Lifetime
- 1994-06-07 AT AT94919201T patent/ATE293127T1/de active
- 1994-06-07 EP EP05007727A patent/EP1595890A3/en not_active Withdrawn
- 1994-06-07 JP JP50183195A patent/JP4205159B2/ja not_active Expired - Fee Related
- 1994-06-07 AU AU70426/94A patent/AU692777B2/en not_active Ceased
-
1995
- 1995-06-07 US US08/487,355 patent/US7514397B1/en not_active Expired - Fee Related
- 1995-11-06 US US08/554,616 patent/US6133418A/en not_active Expired - Lifetime
-
2005
- 2005-04-13 NL NL300192C patent/NL300192I2/nl unknown
- 2005-04-20 LU LU91166C patent/LU91166I2/fr unknown
-
2009
- 2009-11-27 CL CL2009002139A patent/CL2009002139A1/es unknown
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002507576A (ja) * | 1998-03-23 | 2002-03-12 | トリメリス,インコーポレーテッド | ペプチド合成のための方法および組成物 |
JP2010065044A (ja) * | 1998-03-23 | 2010-03-25 | Trimeris Inc | ペプチド合成のための方法および組成物 |
JP2003530311A (ja) * | 1999-07-07 | 2003-10-14 | トリメリス,インコーポレーテッド | ペプチド合成の方法および組成物 |
JP2003504344A (ja) * | 1999-07-09 | 2003-02-04 | トリメリス,インコーポレーテッド | 増強された薬物動態学的性質をもつハイブリッドポリペプチド |
JP2003522948A (ja) * | 2000-02-10 | 2003-07-29 | パナコス ファーマシューティカルズ, インコーポレイテッド | ウイルス融合インヒビターの検出のための分析 |
WO2008050830A1 (fr) * | 2006-10-25 | 2008-05-02 | Kyoto University | Agent anti-vih |
Also Published As
Publication number | Publication date |
---|---|
NL300192I2 (nl) | 2005-08-01 |
CL2009002139A1 (es) | 2010-05-07 |
AU692777B2 (en) | 1998-06-18 |
WO1994028920A1 (en) | 1994-12-22 |
DE69434335D1 (de) | 2005-05-19 |
DE69434335T2 (de) | 2006-02-16 |
PT774971E (pt) | 2005-07-29 |
DE122005000025I2 (de) | 2006-02-09 |
KR960702753A (ko) | 1996-05-23 |
DK0774971T3 (da) | 2005-08-22 |
US5464933A (en) | 1995-11-07 |
LU91166I2 (fr) | 2005-06-20 |
DE122005000025I1 (de) | 2005-08-04 |
JP4205159B2 (ja) | 2009-01-07 |
KR100355407B1 (ko) | 2003-02-07 |
ATE293127T1 (de) | 2005-04-15 |
CA2164698A1 (en) | 1994-12-22 |
EP0774971B1 (en) | 2005-04-13 |
US6440656B1 (en) | 2002-08-27 |
EP1595890A2 (en) | 2005-11-16 |
NL300192I1 (nl) | 2005-07-01 |
EP0774971A4 (en) | 1998-06-10 |
US7514397B1 (en) | 2009-04-07 |
CA2164698C (en) | 2012-10-09 |
NZ267803A (en) | 1999-03-29 |
EP0774971A1 (en) | 1997-05-28 |
NZ329775A (en) | 2000-05-26 |
NZ501727A (en) | 2002-07-26 |
AU7042694A (en) | 1995-01-03 |
ES2238674T3 (es) | 2005-09-01 |
US6133418A (en) | 2000-10-17 |
EP1595890A3 (en) | 2007-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH08511525A (ja) | Hiv伝播の合成ペプチド抑制物質 | |
KR100558087B1 (ko) | Hiv 전이를 포함하는 막-융합 관련된 반응의 저해용 조성물과 반응 | |
CA2224008C (en) | The treatment of hiv and other viral infections using combinatorial therapy | |
WO1996019495A9 (en) | Methods and compositions for inhibition of membrane fusion-associated events, including hiv transmission | |
US6623741B1 (en) | Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission | |
US6750008B1 (en) | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission | |
JP3510249B2 (ja) | C型肝炎ウイルスに特異的な細胞障害性t細胞を刺激するためのペプチド | |
EP0550599A1 (en) | Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus | |
US6713069B1 (en) | Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever | |
Slepushkin et al. | Inhibition of human immunodeficiency virus type 1 (HIV-1) penetration into target cells by synthetic peptides mimicking the N-terminus of the HIV-1 transmembrane glycoprotein | |
US6814968B1 (en) | Inhibition of viral infection and spread with viral and RhoA-derived peptides | |
AU1906592A (en) | Peptides for use in induction of t cell activation against hiv-1 | |
JPH09500096A (ja) | ヒト免疫不全ウイルスに対する予防接種および中和抗体誘発に用いられるペプチド | |
PT671947E (pt) | Composicoes para produzir respostas de linfocitos t citotoxicas contra virus | |
AU714695C (en) | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20031120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040226 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040518 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040915 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20041007 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20050317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070514 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070517 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080207 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080213 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080818 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081016 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111024 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121024 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |